CERRITOS, Calif., Oct. 24, 2016 /PRNewswire/ -- Two new research studies demonstrate how the 1064nm wavelength PerioLase® MVP-7™ dental laser system, optimized for the LANAP® protocol, selectively destroys Porphyromonas gingivalis (Pg), a "keystone" pathogen that directs other gum tissue bacteria to become pathogenically active in the progressive destruction involved in moderate to severe gum disease.
Pg has historically been identified as a black pigmented species bacteria based on its visible color in lab cultures. Numerous studies by Midda and others have shown that Pg is destroyed in human treatments following the use of a 1064nm pulsed Nd:YAG laser. These two observations led to conjecture that Pg was also pigmented in the body (in vivo), and that the 1064nm wavelength kills the bacteria by targeting the visible (black) pigment.
"The Black Bug Myth, Selective Photodestruction of Pigmented Pathogens" by researchers David Harris, PhD, et al., clearly demonstrates that the PerioLase MVP-7 1064nm wavelength dental laser destroys Pg bacteria regardless of the amount of visible pigmentation or complete lack of visible pigmentation in the bacteria.
This research suggests that the PerioLase MVP-7 kills Pg bacteria by destroying an invisible chromophore. In other words, periodontal bugs do not need to be black, or even visible to the human eye, in order to be eliminated by the PerioLase MVP-7.
The second study, "Selective Photoantisepsis", published by Harris and Reinisch, focuses on selectively eliminating pathogens at different depths within a tissue model by analyzing the differences between the absorption of light energy by pathogens and host tissues. The study supports selective destruction of Pg and Prevotella intermedia (Pi) at depths of 3-4mm using a 1064nm pulsed-Nd:YAG laser. Unlike the 1064nm wavelength, the 810nm diode laser requires visible pigment to destroy the bacteria. The 810nm was also lethal to the healthy tissue at an earlier stage. The model indicates no selectivity for the 2940nm Er:YAG laser.
"These two studies add to our understanding of the reasons and mechanisms for the benefits of the PerioLase MVP-7 1064nm pulsed Nd:YAG laser in reducing the periodontal pathogens associated with gum disease," states Robert H. Gregg II, DDS, co-inventor of the PerioLase MVP-7 and inventor of the LANAP protocol. "It is no surprise that positive evidence and research continue to accumulate given the consistent, reproducible results our LANAP-trained clinicians have obtained for decades."
The PerioLase MVP-7 surgical laser, included in the PerioLase Periodontal Package (PPP), is manufactured exclusively by Millennium Dental Technologies, Inc. The PPP includes the industry's best surgical training and the only clinical results guarantee. The patent pending LANAP® Protocol and patent pending LAPIP™ Protocol are featured techniques in the highly acclaimed surgical training program offered by Millennium and presented by the Institute for Advanced Laser Dentistry.
Both studies were published in the journal Lasers in Surgery and Medicine.
ABOUT MILLENNIUM DENTAL TECHNOLOGIES, INC.: Headquartered in Cerritos, Calif., Millennium Dental Technologies, Inc., is the developer of the LANAP® protocol for the treatment of gum disease and the manufacturer of the PerioLase® MVP-7™ digital dental laser. By providing a simple and comfortable experience with unique bone-building clinical results, MDT's FDA-cleared LANAP® protocol removes the fear from gum disease treatment, offering a vastly less painful and less invasive regenerative treatment alternative to conventional surgery. Its PerioLase® MVP-7™ is a 6-watt free-running variable-pulsed Nd:YAG dental laser featuring 7 pulse durations giving it the power and versatility to perform a wide range of soft- and hard-tissue laser procedures. The PerioLase® MVP-7™ is also developed for the LAPIP™ protocol, for the treatment of ailing dental implants. The company's founding clinician, Robert H. Gregg, II, continues to operate the company with the vision: To create better clinical outcomes in periodontal disease patients—and to remain true to the guiding principle—"It's all about the patient." www.lanap.com.
For more information:
Last updated on: 25/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.